Attendee search 

Novelogics Biotechnology Inc. has developed unique next generation antibody immunotherapies for treating multiple types of advanced cancers including colon and prostate cancers.  Immunotherapies for cancer are anticipated to be a $35B per year industry in the upcoming years.  

Cancer Drugs with Safety in Mind

From the beginning the novel and specific design of the therapeutic antibody drug minimizes the potential for autoimmune diseases or harming good cells with the bad.  We are dedicated to making cancer treatments that won't make you sick to get you better.

Unecumbered, Founder Owned

Novelogics has developed their assets in an unecumbered envriornment allowing investors to work directly with the team.  At this time the companyis 100% founder owned and undiluted.  Novelogics is anticipating an early exit and has begun discussions with pharmaceutical companies interested in this area.

In addition; a related Medical Device

In addition to the drug, Novelogics has a second PCT Patent pending for a related medical device with a readily available "go to" market in place. 

Adjuvant Therapeutics Inc. is a clinical stage medical device company that is developing a system to improve the effectiveness of radiotherapy for cancer treatment. The system, called OncO2™, uses innovative technology to increase oxygen concentrations in tumours, making them more sensitive to radiation.

Poor tumour oxygen has long been known to make radiation less effective, particularly in cancers of the head and neck, where 5 year survival rates range from 17% to about 63%. The OncO2™ system allows for individual optimization of therapy to maximize the effectiveness of the radiation.

Adjuvant Therapeutics will initially focus on head and neck cancers, however the OncO2™ system can also address other types of resistant cancers such as those of the cervix and bladder.

Kairos Therapeutics has developed a proprietary next generation antibody-drug conjugate (ADC) platform based on novel toxin, linker and site-specific conjugation technology. Kairos has demonstrated superior pre-clinical in-vivo efficacy over T-DM1. Further pre-clinical studies demonstrate Kairos’ ADCs have superior tolerability and therapeutic index, compared to other leading platforms which may lead to greater clinical efficacy. Through key partnerships, Kairos is developing a novel therapeutic pipeline and is out-licensing its ADC platform to companies seeking access to state-of-the-art technology.  

STRATEGIC CONNECTIONS. CREATIVE SOLUTIONS. Manage your company outreach to investors and partners.

Connecting companies with the right people to build strategic alliances with global partners and investors. Supporting international life science companies in cross border corporate development, financing, investor relations and conference participation. A proven track record leveraging an extensive global network of CEOs, investors and partners into strategic alliances that support business imperatives. CORPORATE DEVELOPMENT - Connecting companies with potential investors and business development opportunities. CONFERENCE ADVISOR Program - A customized program to optimize company participation at key events and conferences to, maximize value and achieve tangible results including online partnering management and management of all conference outreach. 

Aspect Biosystems uses proprietary bioprinting and cell culture technologies to create high quality living 3D human tissues.  We aim to improve the pre-clinical drug discovery process by providing pharmaceutical companies and researchers with functional living tissues that better predict the human response to drugs.  Our testing platforms will enable pharmaceutical customers to identify failed drugs earlier in the development pipeline, before expensive clinical trials begin.  Aspect Biosystem’s long-term vision is to create human tissues on demand for multiple applications including cosmetics-testing, personalized medicine, diagnostics and regenerative medicine.

Pulse Infoframe Inc strives to improve workflow using computer-assisted capture of patient data for specialists – our cloud based software enables better local and global sharing of the data for those who need it to make decisions – our end-user driven tools analyze the data to advance knowledge and thus patient care. Data can be directly entered into our system, and because we sit on top of any EMR system we access additional data that is not otherwise easily accessible. Once accessed, the data is de-identified, aggregated and mined producing meaningful information for our end-users. 

-----------------------

We have applied our solution in various clinical verticals including speciality clinics (Melanoma, Oncology, Neonatology, etc), Imaging and PACS systems (with INFINITT PACS, ClearCanvas, etc) and clinical trials (tracking prostate cancer, Pharmacovigilance, economics, etc). Modules are versatile and can be templated to be used in a variety of systems for achieving the best workflow possible.

PlantForm Corporation is a Canadian company formed in 2008 to commercialize a low-cost, plant-based manufacturing platform for monoclonal antibodies, protein drugs and vaccines for cancer and other critical illnesses.

The company’s technology platform provides several advantages over mammalian cell culture and other fermentation systems used to produce most biologic drugs on the market today: it’s fast, efficient, highly versatile (for new product development) and easily scalable. Best of all, it’s capable of reducing manufacturing costs for life-saving drugs by up to 90 per cent.

PlantForm licenses its technology from the University of Guelph, where it was developed by Dr. J. Christopher Hall, a PlantForm founder and the company’s Chief Scientific Officer. Dr. Hall held the Canada Research Chair in Recombinant Antibody Technology from 2002 to 2014 and is a leading authority in the field. All relevant intellectual property is protected by patent filings.

PlantForm’s pipeline features both innovator and biosimilar products, including:

• biosimilar trastuzumab, a plant-produced version of the $6-billion breast cancer drug Herceptin® (animal studies successfully completed, human clinical trials scheduled for 2014, market entry anticipated 2017)

• biosimilar versions of two additional oncology drugs with combined annual global sales of $11.4 billion (2010)

• innovator antibodies for HIV/AIDS, funded by the Government of Canada and the Bill & Melinda Gates Foundation

• recombinant butyrylcholinesterase (rBuChE), an enzyme used as preventative medicine for people vulnerable to attack by nerve agents, organophosphates or other stimulants ($1.8-million contract with the U.S. Defense Advanced Research Projects Agency and $800,00 contract with Defence Canada)

Fusion Pharmaceuticals is a clinical stage company committed to developing next generation precision radiopharmaceuticals for the diagnosis and treatment of human cancers with unmet medical needs.  The Company’s lead product, FPX-01, combines an alpha radionuclide with the precise targeting of an antibody to cause selective cytotoxicity of tumor cells.  FPX-01 will be entering Phase 2 clinical development in H2, 2015.

CDRD Ventures Inc. (CVI) is the commercialization vehicle of the Centre for Drug Research and Development (CDRD), Canada's national drug development and commercialization center that was founded in 2007 and is based in Vancouver, Canada. CVI seeks to advance promising drug development projects from CDRD using internal funds and through partnerships with international pharmaceutical companies, venture capital firms, biotech companies, and other funding agencies. CVI also seeks to in-license technologies from industry or non-CDRD affiliated research institutions. The firm considers both small molecule and biologic innovative technologies in virtually any therapeutic area.

The National Research Council- Industrial Research Assistance Program (NRC-IRAP) is a Canadian federal government program that offers financial and advisory services to accelerate the growth of businesses through innovation and technology. Regarded worldwide as one of the most successful programs of its kind, NRC-IRAP is a vital component of Canada’s innovation system